Report Description of the APAC Contraceptives Market Analysis
Research Scope and Assumption
- The report provides the market value for the base year 2020 and a yearly forecast up to 2028 in terms of revenue (USD billion)
- The key industry dynamics, regulatory scenario, reimbursement scenario, major market trends, and drug markets are evaluated to understand their impacts on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis
- We have used the combination of top-down and bottom-up approach for market sizing, analyzing key regional markets, dynamics, and trends for various solutions, services, and end uses
- All market estimates and forecasts have been validated through primary interviews with the Key Industry Players (KIPs) and secondary analysis
- Inflation has not been accounted for in order to estimate and forecast the market
- Numbers may not add up due to rounding off
Reason to buy the report:
- Facilitate decision-making based on strong current and forecast data for APAC Contraceptives Market Analysis
- Develop strategies based on the latest regulatory framework
- Strategically analyze micro-markets with respect to individual growth trends, future prospects, and their contribution to the market
- Analyze competitive developments such as expansions, investments, mergers & acquisitions, new product developments, and research & developments in the APAC Contraceptives Market Analysis
- Analyze the opportunities in the market for stakeholders and draw a competitive landscape for market leaders
- To strategically profile key players and comprehensively analyze their market shares and core competencies
- We have technically sound team which do a deep dive research and also provide strategy based consulting analysis
APAC Contraceptives Market Analysis Executive Summary
Contraception is a method of preventing pregnancy using drugs or a device. It is also known as birth control and fertility control. The devices or drugs used in contraception interfere with the normal process of sperm-ovum fertilization to prevent pregnancy.
Market Size and Key Findings
The APAC Contraceptives Market Analysis size stood at around USD 5.74 billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of 6.95% during the forecast period.
The Asia-Pacific contraceptive market is expected to reach at a CAGR of 6.95% during the forecast period 2020-2028.
Market Growth Drivers Analysis
The major factors attributing to the growth of the Asia-Pacific contraceptive drugs and devices market include the necessity to avoid unwanted pregnancies and their complications. The need to avoid unwanted pregnancies, especially in teenage women, is one of the major drivers for this market. It is also observed that more than half of the women identify non-contraceptive health benefits, such as treatment for excessive menstrual bleeding, menstrual pain, and acne, as reasons for use. This is also one of the factors contributing to the growth of the market. The other factors helping the growth of the contraceptives market are the increasing incidence of STDs and the rapid increase in population in the region.
In spite of all these advantages, factors such as lack of acceptance faced by contraceptives are impeding the market growth. Socio-cultural opposition for the use of contraceptives in countries having conservative populations is a major restraining factor. Moreover, lack of accessibility and misperceptions about the use of contraceptives are some of the challenges faced by the contraceptive industry.
COVID-19 impact on “APAC Contraceptives Market”
The COVID-19 epidemic has impacted negatively on healthcare services and technology around the world. It disrupted the demand and supply chain. Due to this pandemic, proper healthcare services and facilities were not available, as supply chains get disrupted, there were limited availability of contraceptives with product shortage & stock outs, lack of trained workers, and due to lack of personal protective equipment to provide safe services, due to the fear of Covid-19.
The Asia-Pacific contraceptive market has been segregated into various categories based on age groups, education, drugs & devices and end users. Companies such as Cooper Surgical, Inc., Merck & Co., Inc., Church & Dwight Co., Inc., Teva Pharmaceutical Industries, Ltd., Apothecus Pharmaceutical Corporation, Pregna, Pfizer, Inc., Bayer AG, Melbea, SMB Corporation, Reckitt Benckiser PLC, Mayer Laboratories, Inc., Ocon Medical, Ltd., Okamoto Industries, Inc., Afaxys, Inc., Allergan, Inc. and Agile Therapeutics have been the leading manufacturers of contraceptives.
Products in Pipeline
- In August 2018, Lupin Pharmaceuticals announced the launch of Drospirenone, Ethinyl Estradiol, and levomefolate Calcium tablets contraceptive drugs in the U.S.
- In May 2018, Aurobindo Pharma launched MILI and TRI-MILI oral contraceptive tablets for use in women to avoid conception.
- In April 2018, Mylan N.V., launched generic YAZ oral contraceptive drug for use by women to avoid unintentional pregnancy.
Notable Recent Deals
- In November 2018, The population Control Council, Los Angeles Bio Medical Research Institute, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), and University of Washington School of Medicine launched first clinical study to test the efficacy and safety of a gel to be used by men for the prevention of unintended pregnancy.
Healthcare Policies and Regulatory Landscape
Policy changes and Reimbursement scenario
More than 218 million women living in developing countries do not want to become pregnant but do not use effective contraceptive methods. For some of them, access to contraception is limited; for others, available methods are not acceptable or affordable. The goal of the Contraceptive Technology Innovation (CTI) Initiative is to develop new and strategically important contraceptives, through a strong focus on global partnerships, that ensures wide access to quality, affordable and acceptable products for those most in need. The CTI Initiative, a project funded by the Bill & Melinda Gates Foundation, is in Phase 2 of implementation. Overall, the CTI Initiative aims to develop new contraceptive products that are safe, effective, low-cost, easy to use and appealing to women in greatest need.
Investment in contraceptive research to identify new products for women has been limited in the pharmaceutical industry relative to investment in drug development for other indications. Pharmaceutical R&D for male contraception was active in the 1990’s but was abandoned over a decade ago. The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) has supported a contraceptive development program since 1969. Through a variety of programs including research grants and contracts, NICHD has developed a pipeline of new targets/products for male and female contraception. A number of lead candidates are under evaluation in the NICHD Contraceptive Clinical Trials Network (CCTN)